Becton Dickinson and Co vs VanEck Gold Miners ETF — how do they compare? Becton Dickinson and Co trades at $156.23 (market cap $41.51B), while VanEck Gold Miners ETF trades at $72.92. The key difference: Becton Dickinson and Co pays a 2.79% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals.
| BDX | GDX | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | — |
52-Week High | $185.39 | $115.84 |
52-Week Low | $135.49 | $51.15 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
GDX, the VanEck Gold Miners ETF, trades at $73.37, down 2.86% in the last 24 hours amid a bearish technical signal from moving averages. The fund's valuation metrics are not available, but recent news highlights competition from lower-fee gold ETFs and a recent addition of Aya Gold & Silver to its holdings. Technical indicators show neutral oscillators with key support at $71 and resistance at $74.
The outlook for GDX is cautious due to underperformance versus physical gold and higher volatility. Investment opportunities lie in potential gold price rebounds and record-high free cash flow yields, but risks include fee disadvantages and sector-specific volatility. Analyst sentiment is mixed, with some seeing a buying opportunity amid low valuations.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →